Virus Name: Rochambeau Abbreviation: RBUV

Status Select Agent SALS Level

Possible Arbovirus No 3

SALS Basis

Isufficient experience with virus; i.e., experience factor from SALS surveys was less than 500 in laboratory facilities with low biocontainment.

Other Information

Antigenic Group Ungrouped

SECTION I - Full Virus Name and Prototype Number

Prototype Strain Number / Designation Accession Number Original Date Submitted CaAr 16102

10/4/1984

Family Genus Not listed Not listed Information From Address

J.P. Digoutte Institut Pasteur, B.P. 304, Cayenne, Guyane Francaise

Information Footnote Reviewed by editor

Section II - Original Source

Isolated By (name) Isolated at Institute J.P. Digoutte and P. Fauran Institut Pasteur, Cayenne

Host Genus Species Host Age/Stage

Coquillettidia albicosta

Sex Female

> **Isolation Details** Isolated From

Signs and Symptoms of Illness Arthropod

Depleted

Time Held Alive before Inoculation

Collection Date Collection Method 9/3/1973 Collected by hand

Place Collected (Minimum of City, State, Country)

Paramana, French Guiana

Latitude Longitude 4° 49' N 53° 38' W

Macrohabitat Microhabitat Method of Storage until

Forest savannah mosaic near Cayenne-Forest at edge of swamp

Inoculated Revco at -70dC

Rochambeau Airport

Footnotes

## Section III - Method of Isolation

Inoculation Date

10/2/1973

Animal (Details will be in Section 6)

nb mice

Route Inoculated Reisolation ic and ip Not tried

Other Reasons

First virus of this type in the laboratory

Homologous Antibody Formation by Source Animal

Test(s) Used

Footnotes

Section IV - Virus Properties

Physicochemical

Pieces (number of genome segments) Infectivity Sedimentation Coefficients(s)

(S)

Percentage wt, of Virion Protein Lipid Carbohydrate

Virion Polypeptides: Number Details

Non-virion Polypeptides: Number Details

Virion Density Sedimentation Coefficients(s)

(S)

Nucleocapsid Density Sedimentation Coefficients(s)

(S)

Stability of Infectivity (effects)

pH (infective range)

Lipid Solvent (ether - % used to test) After Treatment Titer Control Titer

Lipid Solvent (chloroform) After Treatment Titer Control Titer

5% <2.0 dex 6.5 dex

Lipid Solvent (deoxycholate) After Treatment Titer Control Titer

Other (formalin, radiation)

Virion Morphology

Shape Dimensions

Mean Range nm nm

Measurement Method Surface Projections/Envelope Nucleocapsid Dimensions, Symmetry

Morphogenesis

Site of Constituent Formation in Cell Site of Virion Assembly Site of Virion Accumulation

Inclusion Bodies Other

Hemagglutination

Hemaggiutination Antigen Source Erythrocytes (species used)

Goose

No SMB ext. by sucrose-acetone

pH Range pH Optimum

5.8-6.6

Temperature Range Temperature Optimum

Remarks

Serologic Methods Recommended

CF

Footnotes

Section V - Antigenic Relationship and Lack of Relationship to Other Viruses

CF test - homologous titer = 256/64

Institut Pasteur Cayenne [2] - CaAr 16102 antigen gave negative results with immune sera to the following viruses:

Group A; Mucambo, Pixuna, CaAn 410d (Tonate), CaAr 508 (Cabassou), Everglades, Una, Aura, Sindbis.

Group B; yellow fever, St. Louis encephalitis, Ilheus, dengue 2, dengue 3.

Group C; Murutucu, Caraparu, Oriboca. Bunyamwera; Wyeomyia, Maguari, Sororoca.

California; Guaroa.

Simbu; Manzanilla, Ingwavuma, Oropouche, CaAn 1093d (Inini).

Guama, Bimiti, Catu.

Phlebotomus: Itaporanga. Ungrouped: CaAn 128d, CaAr 564, Aruac.

In addition, CaAr 16102 antigen was screened against and gave negative results with NIH immune grouping fluids.

Section VI - Biologic Characteristics Virus Source (all VERTEBRATE isolates) Lab Methods of Virus Recovery (ALL ISOLATIONS) Newborn mice Virus passage Evidence of Infection Cell system (a) history (b) CPE **PLAQUES** Growth Without CPE Day Extent Size (f) Titer Titer Day +/- (g) (c) (d) TCD50/ml (e) (c) PFU/ml (e) Vero (CL) SM 13 No plaques

Vertebrate (species and organ) and arthropod	No. isolations/No. tested	No. with antibody/No. tested Test used	Country and region
Coquillettidia albicosta	1/370 pools		French Guiana (1)

## Section VIII - Susceptibility to Experimental Infection (include viremia)

Experimental host and age	Passage history and strain	Inoculation Route- Dose	Evidence of infection	AST (days)	Titer log10/ml
Mice (nb)	SM 13	ic 0.02	Death	4	6.5
Mice (nb)		ip			
Mice (nb)		sc			
Mice (wn)		ic 0.03	Antibody		
Mice (wn)		ip 0.1	Antibody		

## Section X - Histopathology

2	Section X - Instoputiology	
Character of lesions (specify h	ost)	
Inclusion Bodies	Intranuclear	
Organs/Tissues Affected		
Category of tropism		

Section XI - Human Disease				
In Nature	Residual	Death		
Subclinical	Overt Disease			
Clinical Manifestations				
Number of Cases	Category (i.e. febrile illne	ess, etc.)		
	Section XII - Geograph	nic Distribution		
Known (Virus detected) French Guiana				
Suspected (Antibody only detec	ted)			
8	Section XIII - Re	ferences		
	Annuel de l'Institut Pasteur de la Guy Annuel de l'Institut Pasteur de la Guy			
	Remark	S		